A nanobody against CCL1 protein and its application
CN120209136BActive Publication Date: 2026-05-26GUANGDONG GENERAL HOSPITAL
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- GUANGDONG GENERAL HOSPITAL
- Filing Date
- 2025-03-13
- Publication Date
- 2026-05-26
AI Technical Summary
Technical Problem
Existing technologies struggle to provide a nanobody that binds to the anti-CCL1 protein with high specificity, small molecular weight, and excellent stability for use in tumor immunotherapy.
Method used
Alpaca single-domain antibodies (nanobodies) obtained by screening using phage display technology have amino acid sequences as shown in SEQ ID NO: 1-6. They can specifically bind to CCL1, have small molecular weights, and possess stronger tissue penetration and stability, making them suitable for large-scale industrial production.
Benefits of technology
Nanobodies can effectively block the CCL1-CCR8 axis in tumor immunotherapy, prevent the recruitment and function of Tregs, enhance anti-tumor immune responses, and have low production costs, high safety and efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN120209136B_ABST
Abstract
This invention belongs to the field of biomedical technology, specifically relating to an anti-CCL1 protein nanobody and its applications. This invention screened six nanobodies capable of specifically binding to CCL1 using phage display technology. These nanobodies exhibit strong binding specificity to the CCL1 antigen, can recognize occult epitopes that are difficult for traditional antibodies to bind to, and their small molecular weight gives them stronger tissue penetration while also demonstrating excellent stability. Therefore, the nanobodies of this invention can be used to treat tumors targeting the CCL1-CCR8 signaling pathway. In the immunotherapy of malignant tumors, they effectively block the CCL1-CCR8 axis, thereby enhancing the anti-tumor immune response. Furthermore, they exhibit high sensitivity and specificity in the detection of CCL1 protein, thus showing significant advantages in tumor immunotherapy and CCL1 protein detection.
Need to check novelty before this filing date? Find Prior Art